NR0B1 and gallstones: Statins have been proven to decrease the risk of gallstones’ formation via various mechanisms, including inhibition of hepatic cholesterol biosynthesis by the HMGCR enzyme and activation of the PPAR-γ receptor (a nuclear hormone receptor) [49].